Parkin is an E3 ubiquitin ligase, a type of molecular enzyme that attaches ubiquitin molecules to selected proteins. Ubiquitin is often described as a cellular disposal tag, but that description is incomplete. Depending on the position and structure of the ubiquitin chain, the modification can influence protein stability, location, interactions, or signaling activity. Parkin is central to mitochondrial quality control. When mitochondria become damaged, the kinase PINK1 accumulates on their outer membranes and phosphorylates Parkin, helping activate the enzyme. Parkin then labels mitochondrial proteins with ubiquitin, attracting the autophagy machinery that removes the defective organelle. This process, called mitophagy, prevents damaged mitochondria from releasing toxic signals and helps preserve energy production. Although Parkin phosphorylation has been extensively studied, the researchers say the contribution of Parkin ubiquitination itself has remained unclear, particularly in cancer biology.

To identify relevant ubiquitination sites, the team used mass spectrometry, a highly sensitive analytical method that detects proteins and maps chemical modifications according to their molecular mass. The analysis identified lysine 27 as a site at which Parkin is ubiquitinated. The researchers then replaced this lysine with arginine, generating a mutant known as K27R. Because arginine cannot accept ubiquitin in the same manner as lysine, the substitution creates a ubiquitination-deficient version of Parkin. In cycloheximide chase experiments, which measure how quickly a protein disappears after new protein synthesis is blocked, the K27R mutant declined more rapidly than normal Parkin. This result indicated that ubiquitination at K27 helps protect Parkin from degradation and contributes to its stability. In practical terms, a cell may produce Parkin, but without the correct modification, the protein may not remain present long enough to perform its mitochondrial surveillance role.

The researchers also identified USP10 as a deubiquitinating enzyme that regulates Parkin. Deubiquitinating enzymes remove ubiquitin from proteins and can therefore reverse or reshape the effects of ubiquitination. USP10’s involvement adds another layer to the system: Parkin activity may depend not only on whether K27 is modified, but also on the balance between enzymes that add and remove ubiquitin. Such regulatory balance is common in signaling networks, where rapidly changing protein states allow cells to respond to stress. In cancer, however, disturbances in these controls can favor survival. If Parkin is destabilized or improperly regulated, damaged mitochondria may accumulate, energy production may be remodeled, and stress signals may be redirected toward pathways that support tumor growth.

The K27R mutation affected more than Parkin’s half-life. Experiments showed that the mutant was less capable of moving to mitochondria and interacted less efficiently with PINK1. This is a crucial finding because Parkin must be recruited to damaged mitochondria before it can initiate the ubiquitin-marking cascade required for mitophagy. The weakened interaction also suggested that Parkin phosphorylation was reduced. The relationship appeared to work in both directions. When the researchers used a phosphorylation-deficient Parkin mutant, S65A, the level of Parkin ubiquitination also fell. These observations point to molecular cross-talk: ubiquitination at K27 may help create a stable, activation-ready Parkin molecule, while phosphorylation at serine 65 may reinforce or promote Parkin ubiquitination. Rather than operating as separate switches, the two modifications appear to form an interconnected control circuit.

The consequences became visible at the level of mitochondria. Cells expressing the K27R mutant accumulated higher levels of mitochondrial membrane proteins, including markers associated with the outer and inner mitochondrial membranes. This pattern was consistent with impaired mitophagy, meaning that damaged or surplus mitochondria were not being efficiently cleared. Mitochondrial failure can produce more than an energy deficit. Mitochondria contain their own DNA, and when their membranes become compromised, mitochondrial DNA can escape into the cytoplasm. Because cytosolic DNA resembles a danger signal, it can activate cyclic GMP-AMP synthase, or cGAS. Activated cGAS generates a messenger molecule that stimulates STING, an adaptor protein positioned on intracellular membranes. The cGAS-STING pathway then triggers inflammatory and antiviral gene programs, including the production of interferon-related factors and chemokines such as CXCL10. The study links defective Parkin regulation to this mitochondrial DNA alarm system in cervical cancer cells.

Inflammation generated by cGAS-STING is biologically complex. In healthy tissue, it can help eliminate infected or damaged cells, but persistent activation may reshape the tumor environment and influence cancer-cell survival, immune interactions, and treatment responses. In the experiments, the Parkin mutant was associated with activation of cGAS-STING-related signaling, including increased expression of interferon-associated genes. The findings do not mean that every form of inflammation suppresses cancer or that cGAS-STING activation has a single outcome. Instead, they indicate that defective mitochondrial quality control can alter the signaling landscape within tumor cells. Parkin may therefore act as a connection point between organelle maintenance and innate immune signaling. The effect could be especially important in tumors that rely on metabolic flexibility, allowing them to tolerate mitochondrial damage while using stress responses to persist under challenging conditions.

Metabolic measurements revealed another major shift. Cells carrying the Parkin ubiquitination-deficient mutant showed reduced oxidative phosphorylation, the mitochondrial process that generates ATP through the electron transport chain, while intracellular glycolysis increased. Oxidative phosphorylation is efficient but depends on healthy mitochondria and an intact respiratory system. Glycolysis converts glucose into energy in the cell’s cytoplasm and can continue even when mitochondrial respiration is compromised, although it produces less ATP per molecule of glucose. Cancer cells frequently exploit this flexibility, increasing glucose consumption and lactate production to sustain growth in oxygen-limited or otherwise stressful environments. The researchers assessed these changes using oxygen consumption rate and extracellular acidification rate measurements, which provide functional estimates of mitochondrial respiration and glycolytic activity. The results suggest that loss of properly regulated Parkin pushes cervical cancer cells away from mitochondrial energy production and toward a glycolysis-dominant state.

This metabolic reprogramming was accompanied by more aggressive behavior in laboratory assays. The Parkin mutant promoted tumor spheroid formation, a three-dimensional culture model often used to examine self-renewal, cell survival, and tumor-initiating characteristics. In animal experiments, cells expressing the mutant also accelerated tumor growth. Together, the results support the idea that intact Parkin ubiquitination contributes to tumor suppression, while disruption of the K27-dependent regulatory mechanism weakens mitochondrial quality control and increases malignant potential. The authors propose that Parkin ubiquitination could eventually serve as a biomarker or therapeutic target in cervical cancer. However, the evidence currently comes from molecular experiments, cultured cancer cells, spheroids, and in vivo models rather than from clinical trials. It remains necessary to determine how frequently K27 ubiquitination is altered in patients, whether USP10 activity predicts treatment response, and whether manipulating this pathway can suppress tumors without damaging normal tissues that depend on mitophagy.

The study offers a broader lesson about cancer biology: protein modifications cannot always be understood in isolation. Parkin phosphorylation has long been recognized as a key event in mitophagy, but the new findings show that ubiquitination can influence the protein’s stability, mitochondrial recruitment, phosphorylation state, and downstream effects on immunity and metabolism. A single residue, K27, may therefore help coordinate several layers of cellular decision-making. The work also raises the possibility that therapies aimed at Parkin, USP10, or related enzymes could be combined with treatments targeting metabolism or cGAS-STING signaling. Such strategies would require careful validation, because mitochondrial stress and innate immune activation can have different effects depending on the tumor and its surrounding tissue. For now, the research identifies a previously hidden control mechanism linking Parkin modification to cervical cancer progression and provides a molecular explanation for how defective mitochondrial housekeeping may help tumors survive, adapt, and grow.

Subject of Research: Parkin ubiquitination, mitochondrial quality control, mitophagy, metabolism, and tumor suppression in cervical cancer

Article Title: Ubiquitination of parkin influences its tumor suppressive function in cervical cancer

Article References: Mai, Y., Hua, H., Liang, S. et al. “Ubiquitination of parkin influences its tumor suppressive function in cervical cancer.” Cellular and Molecular Life Sciences (2026).

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06362-3

Keywords: Parkin ubiquitination; Parkin phosphorylation; mitophagy; tumorigenesis; cervical cancer; USP10; cGAS-STING; mitochondrial DNA; oxidative phosphorylation; glycolysis

The crux of the research lies in the identification of UBR5 as a critical tumor suppressor that directly modulates the stability of Snail. Utilizing affinity purification coupled with mass spectrometry, the team isolated UBR5 as an exclusive binding partner of Snail, illuminating a previously underappreciated regulatory axis. Notably, this interaction underscores a post-translational checkpoint essential for maintaining cellular phenotype and metastatic restraint.

Extensive bioinformatic analyses employing datasets from TCGA and GTEx revealed a compelling correlation between UBR5 expression and colorectal cancer progression. Particularly striking was the observation in stage II colorectal tumors where UBR5 expression markedly declined whereas Snail levels surged. This inverse relationship suggests that UBR5 depletion potentiates Snail stabilization during crucial early steps of metastasis, aligning with the biological hallmarks of EMT activation.

Delving deeper, the researchers meticulously defined the domain-specific interaction that underpins this regulation. Through a combination of co-immunoprecipitation assays, protein truncation constructs, and molecular docking simulations, they demonstrated that UBR5 engages Snail via its HECT domain (amino acids 2453–2799), which specifically binds to the C-terminal zinc finger domain of Snail (amino acids 151–264). This nuanced specificity is a remarkable divergence from other known E3 ligase interactions within the RING family, positioning UBR5 as a unique modulator with distinct biochemical properties.

Crucially, the UBR5-mediated regulation of Snail involves targeted K48-linked polyubiquitination leading to proteasomal degradation. This ubiquitination process is not arbitrary but contingent on prior phosphorylation of Snail by GSK-3β, thereby integrating multiple post-translational control layers. The integrity of the HECT domain in UBR5, especially residue Cys2768, was demonstrated to be indispensable for catalyzing this ubiquitination reaction, highlighting the precise molecular requirements for functional suppression of Snail.

Loss-of-function experiments unveiled the biological consequences of UBR5 deficiency: stabilization of Snail protein, downregulation of epithelial marker E-cadherin, and enhanced expression of mesenchymal markers. These molecular alterations synergistically confer increased cellular motility and invasiveness, hallmark traits of aggressive metastatic phenotypes. Importantly, these in vitro findings were recapitulated in vivo using xenograft mouse models, where UBR5 deficiency correlated with accelerated tumor growth and invasive behavior into adjacent tissues.

Further validating the critical role of the catalytic site, the researchers engineered a mutant UBR5 variant harboring the C2768S mutation within the HECT domain. This mutant lost the ability to physically interact with Snail and failed to promote its degradation. In vivo, tumors expressing this catalytically impaired UBR5 mutant exhibited pronounced aggressiveness and tissue infiltration compared to those expressing wild-type UBR5, which displayed significant tumor regression and encapsulation, affirming the therapeutic relevance of UBR5’s enzymatic function.

From a clinical perspective, interrogation of large CRC patient cohorts reinforced the tumor suppressive role of UBR5, revealing its consistent downregulation in colorectal cancer tissues relative to normal counterparts. More importantly, elevated UBR5 expression levels correlated positively with relapse-free survival, positioning UBR5 not only as a molecular guardian against metastasis but also as a promising prognostic biomarker.

This study elegantly elucidates the UBR5-Snail axis as a linchpin in the regulation of epithelial plasticity and metastatic progression. The requirement for GSK-3β-mediated phosphorylation prior to UBR5-dependent ubiquitination signifies an intricate multi-step regulatory cascade, emphasizing the interplay of kinase and ligase activities in EMT control. Such insights enrich our understanding of the molecular pathology underlying CRC and open potential strategies for therapeutic intervention that restore or mimic UBR5 function.

The identification of the zinc finger motif of Snail as the interacting domain further expands the paradigm of transcription factor regulation by ubiquitin ligases. This structural specificity accounts for the lack of interaction with Snail’s close homolog Slug (Snail2), reinforcing the selectivity of the regulatory network and its potential for targeted drug design.

Technologically, the integration of biochemical assays, protein engineering, clinical genomics, and in vivo tumor models offers a robust multi-dimensional platform for dissecting cancer metastasis mechanisms. The combinatorial use of molecular docking simulations validated the physical plausibility of the UBR5-Snail binding interface, exemplifying the power of computational tools in complementing experimental biology.

In conclusion, the work from Jilin University delineates a sophisticated post-translational checkpoint wherein UBR5 operates as a crucial suppressor of colorectal cancer metastasis by orchestrating the degradation of Snail. Its catalytic competency, governed by Cys2768 within the HECT domain, emerges as a molecular switch balancing epithelial identity against mesenchymal transition. Continued exploration of this axis holds significant promise for the development of novel anti-metastatic therapeutics and prognostic markers in colorectal and potentially other cancers.

Subject of Research: Colorectal Cancer, Metastasis, Epithelial-Mesenchymal Transition (EMT), Ubiquitination

Article Title: Identification of UBR5 as a Critical E3 Ligase Modulating Snail Stability and Metastatic Progression in Colorectal Cancer

News Publication Date: Not provided

Web References: http://dx.doi.org/10.1016/j.gendis.2025.101679

Image Credits: Xinyue Zhao, Ruiying Liu, Zhihui Han, Zehao Li, Ling Mei, Yuyang Liu, Xueqi Fu, Yue Jin

Keywords: Colorectal cancer, Metastasis, UBR5, Snail, E3 Ubiquitin Ligase, HECT domain, EMT, Post-translational modification, GSK-3β, Zinc finger domain, Protein degradation, Tumor suppressor